Pattern of metastasis and outcome in patients with breast cancer

Clinical and Experimental Metastasis

Volumn 32, Issue 2, 2015, Pages 125-133

  Gerratana, L ^a,b   Fanotto, V ^a   Bonotto, M ^a   Bolzonello, S ^a   Minisini, A M ^a   Fasola, G ^a   Puglisi, F ^a,b  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

Breast neoplasm; Immunophenotype; Metastatic spread; Outcome measures; Prognostic factors

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAMOXIFEN; TAXANE DERIVATIVE; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; FEMALE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RISK FACTOR; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; TROPISM; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM TUMOR; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SECONDARY; TIME;

BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925539427     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-015-9697-2     Document Type: Article

References (19)

1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. doi:10.3322/caac.20107
2. Sihto H, Lundin J, Lundin M et al (2011) Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res BCR 13:R87. doi:10.1186/bcr2944
3. El Saghir NS, Tfayli A, Hatoum HA et al (2011) Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. Crit Rev Oncol Hematol 80:433–449. doi:10.1016/j.critrevonc.2011.01.010
4. Bonotto M, Gerratana L, Poletto E et al (2014) Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 19:608–615. doi:10.1634/theoncologist.2014-0002
5. Khodari W, Sedrati A, Naisse I et al (2013) Impact of loco-regional treatment on metastatic breast cancer outcome: a review. Crit Rev Oncol Hematol 87:69–79. doi:10.1016/j.critrevonc.2012.12.005
6. Redig AJ, McAllister SS (2013) Breast cancer as a systemic disease: a view of metastasis. J Intern Med 274:113–126. doi:10.1111/joim.12084
7. Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277. doi:10.1200/JCO.2009.25.9820
8. Berman AT, Thukral AD, Hwang W-T et al (2013) Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. Clin Breast Cancer 13:88–94. doi:10.1016/j.clbc.2012.11.001
9. Park S, Koo JS, Kim MS et al (2012) Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 21:50–57. doi:10.1016/j.breast.2011.07.008
10. Lam SW, Jimenez CR, Boven E (2014) Breast cancer classification by proteomic technologies: current state of knowledge. Cancer Treat Rev 40:129–138. doi:10.1016/j.ctrv.2013.06.006
11. Goldhirsch A, Winer EP, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24:2206–2223. doi:10.1093/annonc/mdt303
12. Prat A, Cheang MCU, Martín M et al (2013) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31:203–209. doi:10.1200/JCO.2012.43.4134
13. Park YH, Lee S, Cho EY et al (2010) Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemother Pharmacol 66:507–516. doi:10.1007/s00280-009-1190-7
14. Minisini AM, Moroso S, Gerratana L et al (2013) Risk factors and survival outcomes in patients with brain metastases from breast cancer. Clin Exp Metastasis. doi:10.1007/s10585-013-9594-5
15. Metzger-Filho O, Sun Z, Viale G et al (2013) Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol 31:3083–3090. doi:10.1200/JCO.2012.46.1574
16. Puglisi F, Fontanella C, Numico G et al (2014) Follow-up of patients with early breast cancer: is it time to rewrite the story? Crit Rev Oncol Hematol 91:130–141. doi:10.1016/j.critrevonc.2014.03.001
17. Heitz F, Harter P, Lueck H-J et al (2009) Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer Oxf Engl 45:2792–2798. doi:10.1016/j.ejca.2009.06.027
18. Dawood S, Broglio K, Ensor J et al (2010) Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 21:2169–2174. doi:10.1093/annonc/mdq220
19. Yardley DA, Kaufman PA, Brufsky A et al (2014) Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res Treat 145:725–734. doi:10.1007/s10549-014-2916-8